Aleix Prat
Oncology Department OncologistAbout me
Graduated in Medicine at University of Barcelona (UB) in 2003. In 2008 he obtained a specialty in Medical Oncology, in 2013 he obtained the Extraordinary Doctorate Award from the Autonomous University of Barcelona. Currently the Director Institut of Oncology at Hospital Clínic Barcelona, Professor of Medicine (Medical Oncology) at the UB and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Lab at IDIBAPS. Furthermore, he is the Head of the Breast Cancer programme at IOB- Quiron salud as well as CEO and co-founder of the spin-off called Reveal Genomics, where has been developed the HER2DX® diagnostic test just recognized by TIME as one of the best inventions of 2022.
Featured publications
-
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
Authors: Prat A; Bardia A; Curigliano G; Hammond MEH; Loibl S; Tolaney SM; Viale G.Reference: Jama Oncology 2022. -
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy
Authors: Pascual, T; Fernandez-Martinez, A; Tanioka, M; Dieci, MV; Pernas, S; Gavila, J; Guarnieri, V; Cortes, J; Villagrasa, P; Chic, N; Vidal, M; Adamo, B; Munoz, M; Griguolo, G; Llombart, A; Conte, P; Oliveira, M; Conte, B; Pare, L; Galvan, P; Carey, LA; Perou, C; Prat, A.Reference: Clinical Cancer Research 2021. -
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
Authors: Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P.Reference: Lancet Oncology 2020. -
Immune-related adverse events of checkpoint inhibitors
Authors: Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME .Reference: Nature Reviews Disease Primers 2020. -
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Authors: Schettini F; Pascual T; Conte B; Chic N; Brasó-Maristany F; Galván P; Martínez O; Adamo B; Vidal M; Muñoz M; Fernández-Martinez A; Rognoni C; Griguolo G; Guarneri V; Conte PF; Locci M; Brase JC; Gonzalez-Farre B; Villagrasa P; De Placido S; Schiff R; Veeraraghavan J; Rimawi MF; Osborne CK; Pernas S; Perou CM; Carey LA; Prat A.Reference: Cancer Treatment Reviews 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Authors: Brasó-Maristany F., Griguolo G., Pascual T., Paré L., Nuciforo P., Llombart-Cussac A., Bermejo B., Oliveira M., Morales S., Martínez N., Vidal M., Adamo B., Martínez O., Pernas S., López R., Muñoz M., Chic N., Galván P., Garau I., Manso L., Alarcón J., Martínez E., Gregorio S., Gomis R.R., Villagrasa P., Cortés J., Ciruelos E., Prat A..Reference: Nature Communications 2020. -
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Authors: Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J .Reference: Lancet Oncology 2020. -
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Authors: Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; DIeci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF.Reference: Journal Of The National Cancer Institute 2020. -
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Authors: Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R .Reference: Annals Of Oncology 2019. -
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.
Authors: Paré L, Pascual T, Seguí E, Teixidó C, Gonzalez-Cao M, Galván P, Rodríguez A, González B, Cuatrecasas M, Pineda E, Torné A, Crespo G, Martin-Algarra S, Pérez-Ruiz E, Reig Ò, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Muñoz M, Victoria I, Ruiz G, Viñolas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila MÁ, Juan M, Llovet JM, Reguart N, Arance A, Prat A .Reference: Annals Of Oncology 2018.
Featured Projects
-
Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer
Principal investigator: Aleix Prat AparicioFunder: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede o evento)Code: 201935-30-31-32Duration: 30/07/2020 - 29/07/2023 -
Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer
Principal investigator: Aleix Prat AparicioFunder: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (ParticCode: GCAEC19010PRATDuration: 01/12/2019 - 30/11/2024 -
AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer
Principal investigator: Patricia Galvan, Aleix Prat AparicioFunder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer ResearchCode: BCRF_AACR_18_001Duration: 01/07/2019 - 30/06/2021 -
Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.
Principal investigator: Aleix Prat AparicioCode: 19-IO-011Duration: 01/07/2019 - 30/06/2021 -
Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk
Principal investigator: Aleix Prat AparicioFunder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Fundación Quiron Salaud ; Fundación Quirón SaludCode: TERAPIA_AMIGOS_18_01Duration: 11/02/2019 - 10/02/2022